Cognition Therapeutics (CGTX) Accumulated Depreciation (2020 - 2025)

Cognition Therapeutics (CGTX) has 6 years of Accumulated Depreciation data on file, last reported at $187000.0 in Q4 2025.

• Quarterly Accumulated Depreciation fell 83.82% year-over-year to $187000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $187000.0 (down 83.82% YoY) and the FY2025 annual result came in at $187000.0, down 83.82% from the prior year.
• Accumulated Depreciation fell to $187000.0 in Q4 2025 per CGTX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $1.2 million in Q4 2024 and bottomed at $187000.0 in Q4 2025.
• The 5-year median for Accumulated Depreciation is $953000.0 (2022), against an average of $843000.0.
• The widest annual swing landed in 2021, when Accumulated Depreciation increased 11.97%; it then tumbled 83.82% in 2025.
• Tracing CGTX's Accumulated Depreciation over 5 years: stood at $870000.0 in 2021, then climbed by 9.54% to $953000.0 in 2022, then grew by 10.07% to $1.0 million in 2023, then climbed by 10.2% to $1.2 million in 2024, then plunged by 83.82% to $187000.0 in 2025.
• Per Business Quant, the three latest CGTX Accumulated Depreciation figures stand at $187000.0 (Q4 2025), $1.2 million (Q4 2024), and $1.0 million (Q4 2023).

Peer Comparison